Tracking babies born to moms on rare disease drug
NCT ID NCT05734521
Summary
This study aims to collect safety information on pregnant and breastfeeding women with Pompe disease who are taking the medication Nexviazyme (avalglucosidase alfa). Researchers will follow the women and their babies for up to 10 years to check for any pregnancy complications or effects on the child's health and development. The goal is to better understand the risks and safety of using this treatment during pregnancy and breastfeeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational site worldwide
RECRUITINGBridgewater, New Jersey, 08807, United States
Conditions
Explore the condition pages connected to this study.